Advertisement

Intracranial Stereotactic Radiosurgery in High Risk Patients with Metastases from Radioresistant Primary Tumors

  • Varun Kumar Chowdhry
  • Seung Shin Hahn
Chapter
Part of the Tumors of the Central Nervous System book series (TCNS, volume 11)

Abstract

Traditionally radioresistant brain metastases including melanoma, renal cell carcinoma, and sarcoma have poor outcomes with supportive care and whole brain radiotherapy (WBRT) alone. Although recent advances in biologic and targeted agents have improved systemic disease control in some patients with melanoma and renal cell carcinoma, such agents have poor penetration and are relatively ineffective in controlling brain metastases. Nevertheless, the ability to provide biologically ablative doses of radiotherapy by radiosurgery still can yield excellent local control similar that found in classically non-radioresistant brain tumors. Although conventional radiobiological models suggest that these patients will not respond to conventionally fractionated radiation therapy treatment, stereotactic radiosurgery allows high doses of radiation to be delivered to the target, while minimizing dose to normal tissue. Here we present treatment strategies and clinical outcome data in the management of such patients. Given the excellent local control following radiosurgery in this group of patients we propose that radiosurgery provides a clinical benefit to this group of patients. The use of whole brain radiation therapy should be considered to improve local control, although can be omitted in selected groups of patients.

Keywords

Renal Cell Carcinoma Brain Metastasis Local Control Metastatic Melanoma Metastatic Renal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22(11):2101–2107PubMedCrossRefGoogle Scholar
  2. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner- Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422):1665–1672PubMedCrossRefGoogle Scholar
  3. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22(6):1118–1125PubMedCrossRefGoogle Scholar
  4. Brenner DJ (2008) The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 18(4):234–239PubMedCentralPubMedCrossRefGoogle Scholar
  5. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL (2002) Stereotactic radiosurgery for patients with “radioresistant” brain metastases. Neurosurgery 51(3):656–657PubMedGoogle Scholar
  6. Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH (2002) Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 94(8):2265–2272PubMedCrossRefGoogle Scholar
  7. Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS (1980) Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer 45(4):679–683PubMedCrossRefGoogle Scholar
  8. Carlino MS, Fogarty GB, Long GV (2012) Treatment of melanoma brain metastases: a new paradigm. Cancer J 18(2):208–212PubMedCrossRefGoogle Scholar
  9. Chang EL, Selek U, Hassenbusch SJ 3rd, Maor MH, Allen PK, Mahajan A, Sawaya R, Woo SY (2005) Outcome variation among “radioresistant” brain metastases treated with stereotactic radiosurgery. Neurosurgery 56(5):936–945PubMedGoogle Scholar
  10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516PubMedCentralPubMedCrossRefGoogle Scholar
  11. Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, Urbanic JJ, McMullen KP, Shaw EG, Tatter SB, Ellis TL (2012) The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 116(5):978–983PubMedCentralPubMedCrossRefGoogle Scholar
  12. Decker DA, Decker VL, Herskovic A, Cummings GD (1984) Brain metastases in patients with renal cell carcinoma: prognosis and treatment. J Clin Oncol 2(3):169–173PubMedGoogle Scholar
  13. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134PubMedCrossRefGoogle Scholar
  14. Flannery T, Kano H, Niranjan A, Monaco EA 3rd, Flickinger JC, Kofler J, Lunsford LD, Kondziolka D (2010) Gamma knife radiosurgery as a therapeutic strategy for intracranial sarcomatous metastases. Int J Radiat Oncol Biol Phys 76(2):513–519PubMedCrossRefGoogle Scholar
  15. Fowler JF (1989) The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Br J Radiol 62(740):679–694PubMedCrossRefGoogle Scholar
  16. Hall EJ, Brenner DJ (1993) The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys 25(2):381–385PubMedCrossRefGoogle Scholar
  17. Hall EJ, Giaccia AJ (2006) Cell survival curves. In: Radiobiology for the radiologist, 6th edn. Lippincott, Philadelphia, pp 30–36Google Scholar
  18. Hernandez L, Zamorano L, Sloan A, Fontanesi J, Lo S, Levin K, Li Q, Diaz F (2002) Gamma knife radiosurgery for renal cell carcinoma brain metastases. J Neurosurg 97:489–493PubMedGoogle Scholar
  19. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723PubMedCentralPubMedCrossRefGoogle Scholar
  20. Kirkpatrick JP, Meyer JJ, Marks LB (2008) The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 18(4):240–243PubMedCrossRefGoogle Scholar
  21. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC (1999) Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45(2):427–434PubMedCrossRefGoogle Scholar
  22. Lassman AB, DeAngelis LM (2003) Brain metastases. Neurol Clin 21(1):1–23PubMedCrossRefGoogle Scholar
  23. Lavine SD, Petrovich Z, Cohen-Gadol AA, Masri LS, Morton DL, O’Day SJ, Essner R, Zelman V, Yu C, Luxton G, Apuzzo ML (1999) Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 44(1):59–64PubMedCrossRefGoogle Scholar
  24. Manon R, O’Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, Gilbert M, Mehta M, Eastern Cooperative Oncology Group (2005) Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol 23(34):8870–8876PubMedCrossRefGoogle Scholar
  25. Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD (1998) Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 42(3):581–589PubMedCrossRefGoogle Scholar
  26. Morton GC (2005) The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol) 17(4):219–227CrossRefGoogle Scholar
  27. Muacevic A, Wowra B, Siefert A, Tonn JC, Steiger HJ, Kreth FW (2008) Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J Neurooncol 87(3):299–307PubMedCrossRefGoogle Scholar
  28. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500PubMedCrossRefGoogle Scholar
  29. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17):1485–1489PubMedCrossRefGoogle Scholar
  30. Powell JW, Chung CT, Shah HR, Canute GW, Hodge CJ, Bassano DA, Liu L, Mitchell L, Hahn SS (2008) Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J Neurosurg 109(Suppl):122–128PubMedGoogle Scholar
  31. Rofstad EK (1994) Fractionation sensitivity (alpha/beta ratio) of human melanoma xenografts. Radiother Oncol 33(2):133–138PubMedCrossRefGoogle Scholar
  32. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698–2705PubMedCrossRefGoogle Scholar
  33. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD (2003) Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factorsinfluencing survival and local tumor control. J Neurosurg 98(2):342–349PubMedCrossRefGoogle Scholar
  34. Sin AH, Cardenas RJ, Vannemreddy P, Nanda A (2009) Gamma Knife stereotactic radiosurgery for intracranial metastases from conventionally radioresistant primary cancers: outcome analysis of survival and control of brain disease. South Med J 102(1):42–44PubMedCrossRefGoogle Scholar
  35. Wrónski M, Maor MH, Davis BJ, Sawaya R, Levin VA (1997) External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37(4):753–759PubMedCrossRefGoogle Scholar
  36. Yu C, Chen JC, Apuzzo ML, O’Day S, Giannotta SL, Weber JS, Petrovich Z (2002) Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 52(5):1277–1287PubMedCrossRefGoogle Scholar
  37. Zhivotovsky B, Joseph B, Orrenius S (1999) Tumor radiosensitivity and apoptosis. Exp Cell Res 248(1):10–17PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Department of Radiation OncologySUNY Upstate Medical UniversitySyracuseUSA

Personalised recommendations